Saturday 17 October 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

135.71 1.24 −0.91%

Follow NBIX

Alert me

Market cap: $13.9B
P/E: 19.2×
Fwd P/E: 30.5×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	32.57	29.43	19.63	23.91
P/S ratio Full definition →		5.20	4.93	4.27	5.05
P/FCF ratio Full definition →		23.53	18.85	15.93	19.56
P/Operating CF Full definition →		61.34	36.33	90.81	124.80
P/B ratio Full definition →		4.65	4.34	3.89	4.61
Price to Tangible BV Full definition →		4.70	4.35	3.90	17.60
EV/Sales Full definition →		4.99	4.61	4.02	5.09
EV/EBITDA Full definition →		24.19	20.71	15.48	20.65
EV/Operating CF Full definition →		21.03	16.85	14.45	19.14
EV/FCF Full definition →		22.58	17.61	15.01	19.74
Quick Ratio Full definition →		2.89	2.92	2.51	1.46
Current Ratio Full definition →		3.38	3.39	2.93	1.87
Net Debt/EBITDA Full definition →		(4.52)	(7.20)	(6.56)	(2.17)
Debt/Assets Full definition →		0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →		0.00	0.00	0.00	0.00
Asset Turnover Full definition →		0.69	0.69	0.72	0.73
Operating CF/Net income Full definition →		1.09	2.53	0.74	0.94
Capex/Depreciation Full definition →		(1.71)	(0.46)	(1.25)	(0.28)
Interest Coverage Full definition →		—	—	—	52.24
Research and Development Expense of Revenue Full definition →		31.45%	32.05%	36.37%	34.07%
Selling, General and Administrative Expense of Revenue Full definition →		36.68%	37.47%	39.10%	45.85%
Intangible Assets out of Total Assets Full definition →		0.01	0.00	0.00	0.51
Share Based Compensation of Revenue Full definition →		6.76%	7.27%	7.02%	6.78%
Graham Net Nets Full definition →		0.06	0.08	0.07	0.00
Graham Number Full definition →		54.13	59.55	71.55	76.16
Earnings Yield Full definition →		3.07%	3.40%	5.09%	4.18%
Free Cash Flow Yield Full definition →		4.25%	5.31%	6.28%	5.11%
Revenue per Share Full definition →		8.00	8.10	8.10	9.50
Operating CF per Share Full definition →		2.29	3.90	1.45	1.35
Capex per Share Full definition →		(0.13)	0.02	(0.09)	(0.08)
Free Cash Flow per Share Full definition →		2.16	3.93	1.36	1.27
Cash per Share Full definition →		11.22	14.88	13.10	3.86
Shareholders Equity per Share Full definition →		30.22	32.69	33.90	36.57
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		30.22	32.69	33.90	36.57
Free Cash Flow Full definition →		214.30	390.80	136.70	128.60
Working Capital Full definition →		1,520.40	1,779.30	1,604.40	763.00
Capital Expenditures Full definition →		(13.20)	2.40	(9.10)	(7.80)
Net Current Asset Value Full definition →		896.30	1,144.30	937.30	(28.00)
EV/EBIT Full definition →		24.34	21.30	15.82	21.62
Capex to Sales Full definition →		0.02	0.00	0.01	0.01
Price to Operating Income Full definition →		25.36	22.79	16.78	21.42
Other line items
Average Receivables Full definition →		604.55	582.95	642.05	741.35
Average Payables Full definition →		488.50	567.95	624.10	648.90
Average Inventory Full definition →		57.55	63.20	61.80	80.55
Average Assets Full definition →		3,900.35	4,175.10	4,296.95	4,624.45
Average Common Equity Full definition →		2,861.25	2,921.40	2,971.55	3,193.95

Fold the line items

Columns are period end dates

Stockrow Weekly